Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience
Julius C. Enßle(Goethe University Frankfurt), Björn Steffen(Goethe University Frankfurt), Mathias Haenel(Klinikum Chemnitz), Kerstin Schäfer-Eckhard(Nuremberg Hospital), Markus Schaich(Rems-Murr-Klinikum), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Hans Christian Reinhardt(German Cancer Research Center), Sarah Weber(Boston Children's Hospital), Claudia D. Baldus(University Hospital Schleswig-Holstein), Sebastian Wolf(Goethe University Frankfurt), Dirk Niemann(Gemeinschaftsklinikum Mittelrhein), Andreas Neubauer(RWTH Aachen University), Edgar Jost(Universitätsklinikum Aachen), Leo Ruhnke(Krankenhaus Dresden-Friedrichstadt), Lars Fransecky, Sabrina Kraus(Universitätsklinikum Würzburg), Christoph Schliemann(University Hospital Münster), Andreas Burchert(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Maxi Wass(University Hospital in Halle), Sebastian Scheich(Goethe University Frankfurt), Hubert Serve(Goethe University Frankfurt), Tim Sauer(Heidelberg University), Martina Crysandt(RWTH Aachen University), Martin Kaufmann(Robert Bosch Hospital), Jan‐Henrik Mikesch(University Hospital Münster), Gerhard Held(Saarland University), Michael Krämer(University Hospital Carl Gustav Carus)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k